Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations

Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations

<b>Background/Objectives:</b> Infliximab, ipilimumab, and nivolumab are three monoclonal antibodies that have been associated with hepatotoxicity. Three separate physiologically based pharmacokinetic (PBPK) models were developed in GastroPlus<sup>®</sup> to simulate plasma an...

Full description

Saved in:
Bibliographic Details
Main Authors: Celeste Vallejo, Cameron Meaney, Lara Clemens, Kyunghee Yang, Viera Lukacova, Haiying Zhou
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Pharmaceutics
Subjects:
physiologically based pharmacokinetic model
infliximab
ipilimumab
nivolumab
large molecule
hepatic concentration
Online Access:https://www.mdpi.com/1999-4923/17/3/372
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items